





Please note this documentation is available for various countries all over the world and hence it may contain statements or product classification not applicable to your country. The claims made are in reference to ingredients only, hence they do not refer to finished products and they may not comply with Regulation EC n. 1924/2006. The marketer of any finished product containing any ingredient is responsible for assuring that the destination of the product and the claims made for the finished product are lawful and comply with all applicable laws and regulations of the country or countries in which the product is to be sold.

#### WHAT IS MERIVA®?

MERIVA® is a patent pending delivery form of curcumin. Curcumin typically exhibits poor oral absorption in the body.1 Pharmacokinetic comparison studies have shown MERIVA® to improve bioavailability of curcuminoids by about 30-fold.2,3

Three studies conducted MERIVA® demonstrated significant improvements related to stiffness, muscle soreness, physical function, liver health and overall quality of life. A long term study has shown MERIVA® also to support ocular health, 6,8 confirming the inflammatory response markers support and the excellent safety profile.

# **SPECIFICATIONS**

MERIVA® is standardized to contain 18-22% of total curcuminoids.

#### RECOMMENDED DOSE

MERIVA® is a light orange powder for use in nutritional supplements. Recommended daily dose: 1 g

## SCIENTIFIC EVIDENCE

MERIVA® is overall supported by over 30 humanl studies, involving 2000+ individuals, confirming its high tolerability profile.

### **TRADEMARKS**

MERIVA® is a trademark of Indena S.p.A. and its logo and usage guidelines are available from Indena

- <sup>1</sup> Anand, P. et al., Mol. Pharmaceutics: 2007, 4(6), pp. 807-818. <sup>2</sup>Cuomo J. et al., J Nat Prod. 2011 Mar 17.
- <sup>3</sup> Marczylo T.H. et al., Cancer Chemother. Pharmacol. 2007, 60 (2), 171-7.
- <sup>4</sup> Belcaro G. et al.., Panminerva Medica 2010, 52 (2 Suppl 1), 55-62.
- <sup>5</sup> Belcaro G. et al., Altern Med Rev. 2010, 15(4):337-44
- <sup>6</sup> Allegri P. et al., Clinical Ophtalmology 2010, 4, 1201-1206
- <sup>7</sup> Appendino G. et al., Panminerva Medica 2011, 53 (3 Suppl 1):43-9 Steigerwalt R. et al., Panminerva Med. 2012 54 (Suppl. 1 to No. 4): 11-6 Drobnic F. et al., J Int Soc Sports Nutr. 2014 Jun 18;11:31
- 10 Sciberras JN. et al, J Int Soc Sports Nutr. 2015 Jan 21;12(1):5 11 Franceschi F. et al., Eur Rev Med Pharmacol Sci 2016; 20(4):762-6
- 12 Dugall M. et al., Eur Rev Med Pharmacol Sci 2017; 21 1684-9
- <sup>13</sup> Panahi Y. *et al.*, J Cardiovasc Pharmacol 2016 Sep 68(3): 223-9
- <sup>14</sup> Panahi Y. *et al.*, Drug Res (Stuttg) 2017 Apr: 67(4): 244-251

## WHAT MAKES MERIVA® UNIQUE?

MERIVA® is the 100% natural food grade delivery form of curcumin utilizing Indena proprietary Phytosome® technology, based on dietary-grade adjuvants (lecithin), able to optimize the bioabsorption of the extract.

MERIVA® is the most studied and documented curcumin bioavailable formulation

MERIVA® pharmacokinetic studies demonstrated significant absorption benefits:2,3

ullet Improved plasma  $C_{max}$  and AUC of curcuminoids near 30-fold over the standard turmeric extracts

MERIVA® is supported by more than 30\* human trials demonstrating effectiveness for joint & bone health and healthy inflammatory response after exercise and similar exertion:

- Decreased WOMAC score measuring excercise related pain, stiffness and physical function;4-5
- Social and Emotional Index (SEI) score resulted in a greater than 3-fold improvement;4
- C-Reactive Protein (CRP) levels decreased bv 16-fold:4
- Healthy blood vessel function support.<sup>7</sup>
- Attenuated muscle soreness from oxidative stress and inflammation associated to continuous exercise, statistically significant reduction of IL-8 vs placebo and IL-6. reduction of MRI evidence of muscle stress:9,10
- Improved strenght and physical performance, preventing loss of lean body mass in elderly population;11
- Improved bone density in asymptomatic subjects with a bone density condition<sup>12</sup>
- Improved health status in subjects with non-alcoholic fatty liver disease (NAFLD). 13,14



<sup>\*</sup>Contact Indena directly for the latest available studies